Vidal Health and Serum Institute of India Join Forces, ETHealthworld

Mumbai/Pune: Vidal Health, a wholly owned subsidiary of Health Tech company Bajaj Finserv Health, has partnered with Serum Institute of India (SII), the world’s largest vaccine manufacturer, to support national efforts in cervical cancer prevention and awareness.

Starting October 1, 2025, Vidal Health’s platform will provide a first-of-its-kind, end-to-end digital and cashless HPV vaccination experience. The programme will cover appointment booking, consent, certification, dosage reminders, and adherence monitoring, eliminating paperwork and streamlining continuity of care.

It is indicated that the HPV vaccine will be available directly through Vidal Health’s digital platform, ensuring timely access with no intermediaries. Users will benefit from digital registration, cashless payment, and automated tracking of the multi-dose schedule. Corporates will also have the option to offer vaccinations onsite or at partner clinics.

By connecting healthcare providers, vaccine manufacturers, and national digital platforms such as Aarogya Setu, the collaboration aims to build a stronger ecosystem for preventive care and increase adoption of HPV vaccination.

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!